帕博利珠单抗或安慰剂联合化疗加或不加贝伐珠单抗治疗持续性、复发性或转移性宫颈癌的健康相关生活质量(KEYNOTE-826):随机、双盲、安慰剂对照、3期试验
KEYNOTE-826研究在19个国家151个中心纳入617例持续性、复发性或转移性宫颈癌患者,随机接受帕博利珠单抗或安慰剂联合化疗加或不加贝伐珠单抗。预设次要终点分析显示,第30周QLQ-C30总体健康状况-生活质量评分变化两组间差异为1.0分(95%CI -2.7至4.7),至真实恶化时间HR 0.84(95%CI 0.65-1.09),帕博利珠单抗组42%患者 versus 安慰剂组29%患者报告生活质量改善(p=0.0003)。结论认为加用帕博利珠单抗未对健康相关生活质量产生负面影响。
要点
- 第30周QLQ-C30总体健康状况-生活质量评分变化组间差异为1.0分(95%CI -2.7至4.7)。
- 至真实恶化时间帕博利珠单抗组未达到 versus 安慰剂组12.9个月,HR 0.84(95%CI 0.65-1.09)。
- 帕博利珠单抗组42%患者 versus 安慰剂组29%患者生活质量改善(p=0.0003)。
核心结论
- 在化疗加或不加贝伐珠单抗基础上加用帕博利珠单抗未对健康相关生活质量产生负面影响。
- 结合KEYNOTE-826已报告的疗效和安全性结果,这些数据支持帕博利珠单抗的获益及免疫治疗在复发性、持续性或转移性宫颈癌患者中的价值。
研究设计与样本
- KEYNOTE-826为多中心、随机、双盲、安慰剂对照3期试验,在19个国家151个癌症治疗中心开展。
- 2018年11月20日至2020年1月31日筛查883例患者,617例随机分配(帕博利珠单抗组n=308,安慰剂组n=309)。
- 587例(95%)患者接受至少一剂研究治疗并完成至少一次基线后PRO评估,纳入PRO分析(帕博利珠单抗组n=290,安慰剂组n=297)。
- 患者随机(1:1)接受帕博利珠单抗200 mg或安慰剂每3周静脉给药最多35个周期,联合化疗(紫杉醇175 mg/m2加顺铂50 mg/m2或卡铂曲线下面积5 mg/mL/min,静脉给药)加或不加贝伐珠单抗15 mg/kg每3周静脉给药。
- 随机分组按诊断时转移性疾病、计划贝伐珠单抗使用和PD-L1联合阳性评分分层。
主要发现
- 中位随访22.0个月(IQR 19.1-24.4)。
- 第30周QLQ-C30完成率帕博利珠单抗组199/290例(69%) versus 安慰剂组168/297例(57%);依从率分别为199/211例(94%) versus 168/186例(90%)。
- QLQ-C30总体健康状况-生活质量评分从基线至第30周最小二乘均值变化帕博利珠单抗组为-0.3分(95%CI -3.1至2.6) versus 安慰剂组-1.3分(95%CI -4.2至1.7),组间最小二乘均值变化差异为1.0分(95%CI -2.7至4.7)。
- 总体健康状况-生活质量真实恶化中位时间帕博利珠单抗组未达到(NR;95%CI 13.4个月至NR) versus 安慰剂组12.9个月(95%CI 6.6至NR),HR 0.84(95%CI 0.65-1.09)。
- 研究期间任意时间总体健康状况-生活质量改善帕博利珠单抗组122/290例(42%) versus 安慰剂组85/297例(29%)(p=0.0003)。
关键数值与推荐
- PRO工具包括EORTC生活质量核心30(QLQ-C30)、EORTC宫颈癌模块(QLQ-CX24)和EuroQol-5维度-5水平(EQ-5D-5L)视觉模拟量表,于治疗前、第1-14周期及此后每隔一个周期收集。
- 主要终点为总生存期和研究者按RECIST版本1.1评估的无进展生存期。
- QLQ-C30总体健康状况-生活质量从基线变化为预设次要终点,在PRO全分析人群中评估。
- 其他PRO分析为方案指定的探索性终点。
临床怎么用
- 原文结论为加用帕博利珠单抗未对健康相关生活质量产生负面影响,这些数据支持帕博利珠单抗的获益及免疫治疗在复发性、持续性或转移性宫颈癌患者中的价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this Article, we report patient-reported outcomes (PROs) from KEYNOTE-826. METHODS: KEYNOTE-826 is a multicentre, randomised, phase 3 trial in 151 cancer treatment centres in 19 countries. Eligible patients were aged 18 years or older with persistent, recurrent, or metastatic cervical cancer not previously treated with systemic chemotherapy (previous radiosensitising chemotherapy was allowed) and not amenable to curative treatment and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin area under the curve 5 mg/mL per min, intravenously) with or without bevacizumab 15 mg/kg every 3 weeks intravenously. Randomisation (block size of 4) was stratified by metastatic disease at diagnosis, planned bevacizumab use, and PD-L1 combined positive score. Patients, investigators, and other study personnel involved in study treatment administration or clinical evaluation of patients were unaware of treatment group assignments. PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol-5 dimension-5 level (EQ-5D-5L) visual analogue scale, each collected before treatment at cycles 1-14 and every other cycle thereafter. Primary endpoints were overall survival and progression-free survival per RECIST version 1.1 by investigator review. Change from baseline in QLQ-C30 global health status (GHS)-quality of life (QoL) was a prespecified secondary endpoint and was assessed in the PRO full analysis population (all patients who received at least one dose of study treatment and completed at least one post-baseline PRO assessment). Other PRO analyses were protocol-specified exploratory endpoints. The study is registered with ClinicalTrials.gov, NCT03635567, and is ongoing. FINDINGS: Between Nov 20, 2018, and Jan 31, 2020, of 883 patients screened, 617 were randomly assigned (pembrolizumab group, n=308; placebo group, n=309). 587 (95%) of 617 patients received at least one dose of study treatment and completed at least one post-baseline PRO assessment and were therefore included in the PRO analyses (pembrolizumab group, n=290; placebo group, n=297). Median follow-up was 22·0 months (IQR 19·1-24·4). At week 30, QLQ-C30 completion was 199 (69%) of 290 patients in the pembrolizumab group and 168 (57%) of 297 patients in the placebo group; compliance was 199 (94%) of 211 and 168 (90%) of 186, respectively. The least squares mean change in QLQ-C30 GHS-QoL score from baseline to week 30 was -0·3 points (95% CI -3·1 to 2·6) in the pembrolizumab group and -1·3 points (-4·2 to 1·7) in the placebo group, with a between-group difference in least squares mean change of 1·0 point (95% CI -2·7 to 4·7). Median time to true deterioration in GHS-QoL was not reached (NR; 95% CI 13·4 months-NR) in the pembrolizumab group and 12·9 months (6·6-NR) in the placebo group (hazard ratio 0·84 [95% CI 0·65-1·09]). 122 (42%) of 290 patients in the pembrolizumab group versus 85 (29%) of 297 in the placebo group had improved GHS-QoL at any time during the study (p=0·0003). INTERPRETATION: Addition of pembrolizumab to chemotherapy with or without bevacizumab did not negatively affect health-related quality of life. Along with the efficacy and safety results already reported from KEYNOTE-826, these data support the benefit of pembrolizumab and the value of immunotherapy in patients with recurrent, persistent, or metastatic cervical cancer. FUNDING: Merck Sharp & Dohme.
引用
- Monk BJ, Tewari KS, Dubot C, et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023. PMID: 36878237. doi:10.1016/S1470-2045(23)00052-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。